Updates to the Handbook

There is updated clinical guidance on the use of both zoster vaccines, Zostavax and Shingrix, that is relevant for people aged ≥18 years. Please refer to the ATAGI clinical statement on the clinical use of Zoster vaccine in Australia.

• Updated advice on co-administration of Fluad Quad and Shingrix vaccine has been provided
• Fluzone High-Dose Quadrivalent is registered for use in Australia and is indicated in adults ≥60 years of age.
• The indicated ages for Flucelvax Quad and Influvac Tetra have been extended. Flucelvax Quad can now be used in children ≥2 years of age. Influvac Tetra can now be used in children ≥6 months of age.

Updated influenza vaccine brand in table on components of vaccines used in Australia

Updates to the 'Doses of intramuscular 1:1000 adrenaline for anaphylaxis' table to reflect changes to ASCIA's clinical guidelines on acute management of anaphylaxis (June 2021)

Updates to Table. Catch-up schedule for Haemophilus influenzae type b (Hib) vaccination for children <5 years of age

Changes to the 'People with latex allergy' section under 'Precautions', to reflect updated product information regarding Adacel.

• Added 'People with latex allergy' section under 'Precautions', to reflect updated product information regarding Adacel.

Improved clarity regarding MenB vaccine recommendations for all Aboriginal and Torres Strait Islander people aged 2 months to 19 years are strongly recommended to receive MenB vaccine.

• Added 'People with latex allergy' section under 'Precautions', to reflect updated product information regarding Adacel.

• Improved clarity regarding recommendations to vaccinate infants with underlying conditions that predispose them to severe rotavirus gastroenteritis, despite existing precautions. See 'Infants with underlying conditions that predispose them to severe rotavirus gastroenteritis' under 'Precautions'
• Added relevant information and guidance on interrupted vaccination

• Added 'People with latex allergy' section under 'Precautions', to reflect updated product information regarding Adacel.

Editorial updates to reflect the changes to the NIP, where children >12 months are recommended to receive Men ACWY vaccine (Nimenrix) as opposed to just the Men C vaccine.

Updated guidance regarding 2 doses of varicella-containing vaccine for children aged 12 months to <14 years

Updated advice on co-administration of influenza vaccine and COVID-19 vaccine has been provided.

Guidance on intradermal injection expanded.

Guidance on MenB vaccine minimum intervals updated.

Greater detail provided on dose and administration.

Minor changes based on ATAGI advice. See Vaccination after tetanus-containing vaccines.

• Updated guidance on route of administration.
• Removal of Menitorix as vaccine was discontinued in July 2020.

NCIRS request: Page - Update - Minor corrections.